Cybin Inc. (CYBN)
Cybin Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $8.28, up 1.22% on the session, giving a market capitalisation of $413.0M. On trailing twelve-month figures it carries a trailing P/E of -2.26, a net margin of 0.0%. Its beta of 0.79 implies it has historically moved less than the broad market.
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.
Cybin Inc. is most often compared with the following Healthcare names: